TW464514B - Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate - Google Patents

Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate Download PDF

Info

Publication number
TW464514B
TW464514B TW085116139A TW85116139A TW464514B TW 464514 B TW464514 B TW 464514B TW 085116139 A TW085116139 A TW 085116139A TW 85116139 A TW85116139 A TW 85116139A TW 464514 B TW464514 B TW 464514B
Authority
TW
Taiwan
Prior art keywords
proton pump
coating layer
dosage form
enteric coating
patent application
Prior art date
Application number
TW085116139A
Other languages
English (en)
Chinese (zh)
Inventor
Helene Depui
Agneta Hallgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20400969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW464514(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Application granted granted Critical
Publication of TW464514B publication Critical patent/TW464514B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW085116139A 1996-01-08 1996-12-27 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate TW464514B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600071A SE9600071D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients I

Publications (1)

Publication Number Publication Date
TW464514B true TW464514B (en) 2001-11-21

Family

ID=20400969

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085116139A TW464514B (en) 1996-01-08 1996-12-27 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate

Country Status (34)

Country Link
US (1) US6183776B1 (enExample)
EP (1) EP0813424B2 (enExample)
JP (1) JPH11501950A (enExample)
KR (1) KR100490075B1 (enExample)
CN (1) CN1080125C (enExample)
AR (1) AR005281A1 (enExample)
AT (1) ATE228009T1 (enExample)
AU (1) AU712669B2 (enExample)
BR (1) BR9607350B1 (enExample)
CA (1) CA2213996C (enExample)
CZ (1) CZ293583B6 (enExample)
DE (1) DE69624907T3 (enExample)
DK (1) DK0813424T4 (enExample)
EE (1) EE04002B1 (enExample)
EG (1) EG23821A (enExample)
ES (1) ES2185817T5 (enExample)
HU (1) HU229153B1 (enExample)
IL (1) IL121651A (enExample)
IS (1) IS2716B (enExample)
MX (1) MX9706785A (enExample)
MY (1) MY116091A (enExample)
NO (1) NO326656B1 (enExample)
NZ (1) NZ325977A (enExample)
PL (1) PL187075B1 (enExample)
PT (1) PT813424E (enExample)
RU (1) RU2179453C2 (enExample)
SA (1) SA97170553B1 (enExample)
SE (1) SE9600071D0 (enExample)
SK (1) SK283695B6 (enExample)
TR (1) TR199700916T1 (enExample)
TW (1) TW464514B (enExample)
UA (1) UA45392C2 (enExample)
WO (1) WO1997025066A1 (enExample)
ZA (1) ZA9610935B (enExample)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
JP2001509791A (ja) * 1996-11-27 2001-07-24 ザ、プロクター、エンド、ギャンブル、カンパニー 胃腸障害の治療用組成物及び方法
MX9703918A (es) * 1997-05-28 1998-11-30 J Marshall M D Barry Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior.
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
JP2001513570A (ja) * 1997-08-25 2001-09-04 ザ、プロクター、エンド、ギャンブル、カンパニー 上部胃腸管不調治療用複合製剤
US6328993B1 (en) * 1997-12-08 2001-12-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for an acid liable active proton pump inhibitor
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774906B1 (fr) * 1998-02-13 2000-05-12 Rhodia Chimie Sa Systeme d'encapsulation a coeur organique et a ecorce minerale a base d'hydroxycarbonate d'aluminium et son procede de preparation
CN1195500C (zh) * 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
CA2581111A1 (en) 1998-07-28 2000-02-10 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
MXPA01009934A (es) * 1999-03-29 2002-06-21 American Home Prod Sistema de recubrimiento.
EP1210091A4 (en) * 1999-07-12 2009-07-29 Smithkline Beecham Corp TREATMENT OF STOMACH BREEDERS
US7220762B1 (en) 1999-10-20 2007-05-22 Eisai R&D Management Co., Ltd. Methods for stabilizing benzimidazole compounds
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
AR034757A1 (es) * 2001-07-16 2004-03-17 Astrazeneca Ab Formulacion farmaceutica que comprende un inhibidor de bomba de protones y antiacidos
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
US20040213848A1 (en) 2001-09-28 2004-10-28 Shun-Por Li Modified release dosage forms
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7008777B2 (en) 2001-10-15 2006-03-07 Barry J. Marshall System for the detection of urease and method for using same
US6929926B2 (en) 2001-10-15 2005-08-16 Barry J. Marshall Composition for the detection of gastrointestinal disorders
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
KR100479637B1 (ko) * 2002-02-01 2005-03-31 한국화학연구원 란소프라졸을 함유하는 경구제제 및 그의 제조방법
CO5400144A1 (es) * 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
ES2320438T7 (es) 2002-04-09 2013-02-14 Flamel Technologies Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s)
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040081700A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Dose titratable liquid dosage forms of acid labile drugs
RU2211039C1 (ru) * 2002-08-01 2003-08-27 Наркевич Владимир Эдуардович Антацидный препарат многослойного действия "полигель" для лечения язвенной болезни желудка и двенадцатиперстной кишки
US6663892B1 (en) * 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7258981B2 (en) * 2003-01-24 2007-08-21 Clontech Laboratories, Inc. Sensitive proteasome sensor constructs and methods for their design and use
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
EP1759692A3 (en) * 2003-03-10 2007-09-12 Novartis AG Taste-masked solid veterinary compositions
JP4669391B2 (ja) * 2003-03-18 2011-04-13 興和株式会社 制酸剤組成物
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050037070A1 (en) * 2003-07-18 2005-02-17 Santarus, Inc. Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
AR045061A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
US7252665B2 (en) * 2003-10-31 2007-08-07 Medtronic, Inc Ablation of stomach lining to reduce stomach acid secretion
US7282050B2 (en) * 2003-10-31 2007-10-16 Medtronic, Inc. Ablation of exterior of stomach to treat obesity
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US7041124B2 (en) * 2003-12-23 2006-05-09 Kimberly-Clark Worldwide, Inc. System and method for providing therapy to a portion of a body
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
RU2288725C2 (ru) * 2004-05-31 2006-12-10 Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") Твердая лекарственная форма, проявляющая антацидное действие
CA2569961A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc Controlled release pharmaceutical formulation
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
SE530605C2 (sv) * 2005-09-29 2008-07-15 Barbara Nelson Läkemedel innehållande ett syrahämmande medel, avseende att användas för att motverka och bota luftvägssjukdomar
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
BRPI0620787A2 (pt) * 2005-12-28 2011-11-22 Takeda Pharmaceutical preparação sólida
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US20090068263A1 (en) * 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
AR056062A1 (es) 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术（石家庄）有限公司 一种奥美拉唑组合物及其制备方法
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CN101259140B (zh) * 2007-03-08 2012-08-22 重庆北碚现代应用药物研究所 一种治疗胃炎、胃溃疡及十二指肠溃疡的复方药物及其制备方法
DK2152250T3 (da) * 2007-05-07 2019-12-09 Evonik Degussa Gmbh Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse
EP2044929A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Oral fast distintegrating tablets
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
AU2009215514B9 (en) 2008-02-20 2014-01-30 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
EP2127643A1 (de) * 2008-05-30 2009-12-02 Bayer Schering Pharma Aktiengesellschaft Orale Pelletformulierungen mit zeitversetzter Wirkstofffreigabe
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
WO2010038241A2 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
KR20120030106A (ko) 2009-06-25 2012-03-27 아스트라제네카 아베 Ｎｓａｉｄ-연관된 궤양의 발생 위험이 있는 환자의 치료 방법
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
WO2011131203A2 (en) 2010-04-23 2011-10-27 S-Biotek Holding Aps A solid pharmaceutical composition for neutralizing stomach acid
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US20150238514A1 (en) * 2014-02-21 2015-08-27 William Armstrong Protective Supplement Configuration
US20170042806A1 (en) * 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20190151297A1 (en) * 2016-04-29 2019-05-23 Nauts Equine Brand Pty Ltd Veterinary Composition
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TR201723199A2 (tr) * 2017-12-30 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Yeni farmasötik bileşimler.
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) * 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102146395B1 (ko) * 2018-08-23 2020-08-20 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
BR112022007223A2 (pt) * 2019-10-17 2022-07-05 Hanmi Pharm Ind Co Ltd Composição farmacêutica e formulação de combinação farmacêutica
EP4070789A4 (en) * 2020-01-23 2024-01-24 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING A PROTON PUMP INHIBITOR AND AN ANTIACID
US20230058432A1 (en) * 2020-01-23 2023-02-23 Hanmi Pharm. Co., Ltd. Pharmaceutical composite formulation comprising proton pump inhibitor and antacid
KR102608889B1 (ko) * 2020-07-14 2023-12-04 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법
KR20220065997A (ko) * 2020-11-13 2022-05-23 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
KR20230097346A (ko) * 2021-12-24 2023-07-03 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 경구용 복합정제의 제조방법 및 이에 의해 제조된 경구용 복합정제
KR102553713B1 (ko) * 2022-11-18 2023-07-10 고덕상 미네랄 촉매제를 이용한 양식어류사료 제조방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
EP0153105B1 (en) 1984-02-10 1992-09-09 Benzon Pharma A/S Diffusion coated multiple-units dosage form
US4568560A (en) 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
WO1987004077A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
US5112813A (en) 1986-03-07 1992-05-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Process for the preparation of a viscosity-stable antacid composition
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DK179687D0 (da) 1987-04-08 1987-04-08 Farma Food As Praeparat
ATE73328T1 (de) † 1987-05-08 1992-03-15 Smith Kline French Lab Pharmazeutische zusammensetzungen.
KR960011236B1 (ko) † 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형
GB8809421D0 (en) * 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
AU627775B2 (en) 1988-09-20 1992-09-03 Glaxo Group Limited Pharmaceutical compositions
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
DE4023028A1 (de) * 1990-07-20 1992-01-23 Hoechst Ag Ferroelektrische fluessigkristalline si-enthaltende copolymere, ein verfahren zu ihrer herstellung, mischungen dieser copolymere mit niedermolekularen fluessigkristallen und die verwendung in elektrooptischen bauteilen
US5244670A (en) * 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3142919B2 (ja) 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5229137A (en) † 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
US5447918A (en) 1992-07-27 1995-09-05 Mccullough; Ricky W. Gastrointestinal anti-irritant composition comprising sucralfate and methods of use
NZ253999A (en) 1992-08-05 1996-07-26 Faulding F H & Co Ltd Pelletised substained release medicament
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
CA2110313C (en) † 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
WO1995001780A1 (en) † 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate combinations
JPH08512321A (ja) 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−アルギネート−制酸剤の組合せ物
AU7833194A (en) 1993-09-20 1995-04-10 Procter & Gamble Company, The Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
JP3710473B2 (ja) † 1993-10-12 2005-10-26 三菱ウェルファーマ株式会社 腸溶性顆粒含有錠剤
GB2285989A (en) 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
AUPM596894A0 (en) 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
WO1996001623A1 (en) 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
AUPM695294A0 (en) 1994-07-20 1994-08-11 Borody, Thomas Julius Improved combination therapy dose unit
EP0814773B1 (en) 1995-03-17 2001-07-25 The Boots Company PLC Pectin liquid pharmaceutical compositions
US5824339A (en) † 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
JP2001509791A (ja) 1996-11-27 2001-07-24 ザ、プロクター、エンド、ギャンブル、カンパニー 胃腸障害の治療用組成物及び方法

Also Published As

Publication number Publication date
IL121651A0 (en) 1998-02-08
NO974071L (no) 1997-10-17
DE69624907T2 (de) 2003-08-21
DE69624907T3 (de) 2010-01-14
IS2716B (is) 2011-02-15
EP0813424A1 (en) 1997-12-29
PL322175A1 (en) 1998-01-19
IL121651A (en) 2003-05-29
KR19980702829A (ko) 1998-08-05
TR199700916T1 (xx) 1997-12-21
DK0813424T3 (da) 2003-03-10
ZA9610935B (en) 1997-07-08
EP0813424B1 (en) 2002-11-20
NO974071D0 (no) 1997-09-04
NZ325977A (en) 1999-02-25
JPH11501950A (ja) 1999-02-16
AR005281A1 (es) 1999-04-28
MY116091A (en) 2003-11-28
SE9600071D0 (sv) 1996-01-08
HK1001763A1 (en) 1998-07-10
DE69624907D1 (de) 2003-01-02
EE04002B1 (et) 2003-04-15
UA45392C2 (uk) 2002-04-15
HU229153B1 (en) 2013-09-30
ES2185817T5 (es) 2009-11-24
US6183776B1 (en) 2001-02-06
SK283695B6 (sk) 2003-12-02
AU1324197A (en) 1997-08-01
HUP9904024A2 (hu) 2000-05-28
EG23821A (en) 2007-09-19
EP0813424B2 (en) 2009-08-05
ATE228009T1 (de) 2002-12-15
BR9607350B1 (pt) 2010-08-10
WO1997025066A1 (en) 1997-07-17
PT813424E (pt) 2003-03-31
SK116997A3 (en) 1998-05-06
CN1183047A (zh) 1998-05-27
KR100490075B1 (ko) 2005-09-08
ES2185817T3 (es) 2003-05-01
BR9607350A (pt) 1997-12-30
PL187075B1 (pl) 2004-05-31
CA2213996A1 (en) 1997-07-17
CZ274797A3 (cs) 1998-03-18
SA97170553B1 (ar) 2006-06-04
IS4548A (is) 1997-08-20
RU2179453C2 (ru) 2002-02-20
EE9700192A (et) 1998-02-16
CN1080125C (zh) 2002-03-06
CA2213996C (en) 2006-08-29
AU712669B2 (en) 1999-11-11
HUP9904024A3 (en) 2002-03-28
MX9706785A (es) 1997-11-29
NO326656B1 (no) 2009-01-26
HK1017992A1 (en) 1999-12-10
CZ293583B6 (cs) 2004-06-16
DK0813424T4 (da) 2009-11-09

Similar Documents

Publication Publication Date Title
TW464514B (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
TW452495B (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
AU695966B2 (en) Multiple unit tableted dosage form I
TW421599B (en) Multiple unit pharmaceutical preparation
CA2214033C (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
JP4907765B2 (ja) 経口医薬パルス放出剤形

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees